Myeloid Angiogenic Cells Act As Alternative M2 Macrophages And Modulate Angiogenesis Through Interleukin-8

Reinhold J Medina, Christina L O'Neill, T Michelle O'Doherty, Henry Knott, Jasenka Guduric-Fuchs, Tom A Gardiner, and Alan W Stitt

Endothelial progenitor cells (EPCs) promote angiogenesis and may be feasible tools for treating ischaemic disease. Studies have shown one subtype of EPCs, myeloid angiogenic cells (MACs), to be monocytic cells without endothelial characteristics. Medina et al. studied molecular mechanisms to determine whether these cells could be linked to alternative M2 macrophages. Transcriptomic and immunophenotypic analysis found that MACs express typical M2 markers and indicated MACs as an alternative to M2 macrophages. These results suggest that MACs are capable of promoting repair and limiting tissue injury. In the context of ischaemic injury, the authors showed that intra-vitreal delivery of MACs into the ischaemic eye can effectively promote retinal vascular repair and reperfusion. These results could aid in the development of MAC based therapeutic tools for treatment of ischaemia.

View article PDF

Supplemental Data
Supplemental Video


Posted by Leah Caracappa on Oct 7, 2011 12:00 AM CDT